High dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma
- 15 December 1996
- Vol. 78 (12) , 2502-2509
- https://doi.org/10.1002/(sici)1097-0142(19961215)78:12<2502::aid-cncr9>3.0.co;2-l
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- A new preparatory regimen for autologous bone marrow transplantation for patients with lymphomaCancer, 1995
- Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1994
- High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplantsBlood, 1994
- Limited value of myeloablative therapy for late multiple myelomaBlood, 1994
- Monoclonal antibody-purged bone marrow transplantation therapy for multiple myelomaBlood, 1993
- High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patientsBlood, 1993
- Intensive combined therapy for previously untreated aggressive myelomaBlood, 1992
- Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease.Journal of Clinical Oncology, 1991
- Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factorsBlood, 1990
- HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMAThe Lancet, 1983